Royalty Pharma plc (RPRX) Total liabilities 2019–2025
Royalty Pharma plc (RPRX) total liabilities at each fiscal year-end, per SEC filings.
$9.9BFY2025 · since FY2019: $6.3B → $9.9B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $9.9B | +25.7% |
| FY2024 | $7.9B | +25.1% |
| FY2023 | $6.3B | -13.6% |
| FY2022 | $7.3B | +0.3% |
| FY2021 | $7.3B | +18.7% |
| FY2020 | $6.1B | -2.9% |
| FY2019 | $6.3B | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RPRX financial trends
RPRX RevenueRPRX Net incomeRPRX Net marginRPRX Gross profitRPRX Gross marginRPRX Operating incomeRPRX Operating marginRPRX Operating cash flowRPRX Free cash flowRPRX Capital expendituresRPRX Return on equityRPRX Stock buybacksRPRX Dividends paidRPRX Total assetsRPRX Shareholders’ equityRPRX overview →